Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

MLA

Sebastian Bauer, et al. “Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.” Clinical Cancer Research, vol. 27, Sept. 2021, pp. 6333–42. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-21-1864.

APA

Sebastian Bauer, Steven Attia, Hans Gelderblom, Peter Reichardt, Gina Z. D’Amato, Michael Heinrich, Julie Meade, Patrick Schöffski, Suzanne George, John Zalcberg, Margaret von Mehren, Jean-Yves Blay, Rodrigo Ruiz-Soto, Ping Chi, César Serrano, Robin L. Jones, & Ying Su. (2021). Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clinical Cancer Research, 27, 6333–6342. https://doi.org/10.1158/1078-0432.ccr-21-1864

Chicago

Sebastian Bauer, Steven Attia, Hans Gelderblom, Peter Reichardt, Gina Z. D’Amato, Michael Heinrich, Julie Meade, et al. 2021. “Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.” Clinical Cancer Research 27 (September): 6333–42. doi:10.1158/1078-0432.ccr-21-1864.